Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases

Introduction. Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging resection, incidence of metastases, and limited efficacy of systemic therapies. Methods. A medical record search engine was queried to identify patients diagnosed with PC...

Full description

Saved in:
Bibliographic Details
Published in:Complexity (New York, N.Y.) N.Y.), 2019, Vol.2019 (2019), p.1-6
Main Authors: Chugh, Rashmi, Baker, Laurence H., Shango, Maryann M., McHugh, Jonathan B., Leja, Monika, Zhao, Lili, Siontis, Brittany L., Schuetze, Scott M.
Format: Article
Language:English
Subjects:
Atrium
Brain cancer
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Comparative analysis
Demographics
Diagnosis
Health aspects
Heart
Histology
Internet/Web search services
Liver
Malignancy
Medical records
Metastases
Metastasis
Neuroimaging
Oncology
Patients
Pericardium
Prognosis
Radiation therapy
Sarcoma
Surgery
Thoracic surgery
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging resection, incidence of metastases, and limited efficacy of systemic therapies. Methods. A medical record search engine was queried to identify patients diagnosed with PCS from 1992 to 2017 at the University of Michigan. Results. Thirty-nine patients with PCS had a median age of 41 years (range 2–77). Common histologies were angiosarcoma (AS, 14), high-grade undifferentiated pleomorphic sarcoma (UPS, 10), and leiomyosarcoma (LMS, 5). Sites of origin were left atrium (18), right atrium (16), and pericardium (5). AS was the most common right-sided tumor; UPS was more common on the left. Eighteen patients presented with metastases involving lung (10), bone (7), liver (5), and brain (4). Twenty-five patients underwent resection, achieving 3 R0 resections. Patients received a median of 2 (1–6) systemic therapies. Median overall survival (OS) was 12.1 months (range 0–79). Median OS was 14.0 months and 8.2 months in patients who did or did not undergo resection, respectively (p=0.018). Brain metastases occurred in 12 (31%) patients, 9 (75%) of whom had left heart tumors, at a median of 8.5 months (range 0–75) from diagnosis. Median OS was 5.6 months (range 0–30) after the diagnosis of brain metastases. Conclusions. PCS portends a poor prognosis, because of difficulty in obtaining complete resection of sarcoma, advanced stage at diagnosis, and high risk of brain metastases. Providers should be aware of the increased risk of brain metastases and consider brain imaging at diagnosis and follow-up.
ISSN:1076-2787
1357-714X
1099-0526
1369-1643
DOI:10.1155/2019/1960593